Business Wire - April 13, 1999 08:46
LA JOLLA, Calif.--(BW HealthWire)--April 13, 1999--La Jolla Diagnostics Inc. (OTCBB:LAJD), announced that it has signed a letter of intent with the Angelini Group, a leading Italian pharmaceutical firm.
The letter of intent covers certain La Jolla Diagnostics' products and technologies, including ophthalmic solutions and nasal sprays, that Angelini wishes to evaluate for introduction into the European market.
Under the letter of intent Angelini will have exclusive territorial rights to the La Jolla Diagnostic products and technology that it introduces in the countries of Italy, Spain, Portugal, Greece, Turkey, and other areas as agreed upon by the parties. Angelini is the third largest privately held pharmaceutical company, and the leading OTC firm, in Italy, with total gross sales of over $1.7 billion in 1997.
La Jolla Diagnostics is an emerging company engaged in the development and marketing of state-of-the-art diagnostic tests, health care products and nutraceuticals.
CONTACT: La Jolla Diagnostics Inc.
Don Brucker, 800/454-6790, Fax 619/454-7851
lajd96@aol.com
lajd.com
This is my opinion only: But until Mr.Brucker learns to write a press release that gives some numbers, we will continue to see this company sit right around the same area.
I have asked him to elaborite and provide some meat and potato's but here is another example of the same stuff.
Regards
Jeff |
